drugset
Drugs / Hyperpolarized 13C,15N2-urea
last change Jan 2019 re-read 2 minutes ago

Hyperpolarized 13C,15N2-urea

Diagnostic / imaging agent

Investigated by
American Cancer Society, Inc. · National Cancer Institute (NCI) · Ivan de Kouchkovsky, MD · National Institute for Biomedical Imaging and Bioengineering (NIBIB) · Zhen Wang, MD

Trials 2 · a red edge is where a trial was stopped

today NCT04258462 · Ph 2 NCT02526368 · Ph 0
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT02526368 Mar 2016 → Dec 2026 expected prostate carcinoma Ivan de Kouchkovsky, MD Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT04258462 Jan 2019 → Oct 2026 expected kidney benign neoplasm, renal cell carcinoma Zhen Wang, MD Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Hyperpolarized 13C,15N2-urea ClinicalTrials.gov intervention name — accepted as the source's own label NCT04258462 ↗
1

NCT02526368 ↗
Modality Diagnostic / imaging agent “Diagnostic (Combined (co-polarized) HP 13C pyruvate and 13C, 15N2 Urea with MRI)” NCT04258462 ↗
Route Intravenous “Given IV” NCT04258462 ↗